As described in the Leadership and Administration Core, an interdisciplinary group of senior leaders is available to interact with each other on a variety of substantive committees - two of which serve to evaluate developmental research studies and guide decision making on the use of stored specimens or the collection of prospective specimens needed to conduct these studies. In this section of the SPORE proposal we describe the allocation of SPORE resources to DRP projects. There are four kinds of SPORE resources: funding to support the research costs of developmental studies, access to stored specimens for use in developmental studies, access to a patient population with the potential to collect prospective specimens to support developmental studies, and data describing prior characterization of banked annotated specimens. In recognition of rapidly changing technology and new and novel applications of such technology for research, approximately $176,000 in total costs will be available per year in the Developmental Research Program (DRP) budget. Matching institutional funds from Fred Hutchinson Cancer Research Center (FHCRC) will be available at the discretion ofthe PI for outstanding ovarian SPORE developmental research projects that address SPORE priorities in risk assessment and early detection, immunotherapy, molecular signatures, and development of novel treatments of ovarian cancer (see FHCRC letter of institutional commitment). Through early detection we hope to improve outcomes significantly, because 1) currently available treatments are more effective in disease confined to the ovary, and 2) we will develop novel, relatively non-toxic treatments that will be particularly effective in early-stage disease. The tools of molecular biology, immunology and immunotherapy are emphasized in the translational research program. The POCRC is a community based, multidisciplinary, translational research program that involves clinicians, laboratory scientists and public health scientists from several research and medical institutions in the region. The broad based approach takes full advantage ofthe scientific expertise available locally and allows the pooling of clinical resources, thus facilitating population-based studies despite the low incidence of ovarian cancer. Applications will be solicited annually for use of these funds, and each application will be reviewed for its scientific merit and its resource needs including access to specimens. This section of the SPORE application outlines the POCRC's system for evaluation of developmental research study applications and progress. It also includes a summary report on previously funded or on-going projects, as well as several examples of projects that might be initiated next year if funding is available. Dr. Martin Mcintosh, program leader, will oversee this program and the Executive Committee will evaluate the progress ofthe funded developmental research studies. This program has, and will continue to be, flexible in nature and funding priorities will change according to scientific needs ofthe overall program. Exciting laboratory science with translational potential is a high priority. DRP applications should be designed to develop within a couple years into full-scale translational research projects suitable for a SPORE or ROI application. As collaboration between a laboratory, clinical and/or public health scientist greatly facilitates translational research, DRP projects are usually co-directed by an interdisciplinary team of two investigators. Inclusion of a POCRC/SPORE investigator as a co-director facilitates integration with SPORE themes and appropriate use of the SPORE core resources. Since 1999, the POCRC DRP has funded 29 developmental research proposals with approximately $1.5 million in total funding support. A total of 66 applications have been reviewed, for a funding rate of 44%. We will continue to use the current peer-review process to select new projects to be supported by SPORE resources, as it has been very successful.. SPORE funds have been awarded to highly meritorious applicants proposing studies that complement on-going POCRC projects and meet translational research criteria each year. Six of the DRP awards have led to new projects (Projects 4 and 5) or new roles in the next funding period for an investigator (Tewari, Swisher, Salazar, and Knudsen). DRP funds have been used to grow new scientific projects and project leaders in the current SPORE award and in this application, as can be seen in Table 1. The process that is in place will be used during the next funding period, as described below.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Fred Hutchinson Cancer Research Center
United States
Zip Code
Hooda, Jagmohan; Novak, Marian; Salomon, Matthew P et al. (2018) Early loss of Histone H2B monoubiquitylation alters chromatin accessibility and activates key immune pathways that facilitate progression of ovarian cancer. Cancer Res :
Kondrashova, Olga; Topp, Monique; Nesic, Ksenija et al. (2018) Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nat Commun 9:3970
Liu, Joyce F; Palakurthi, Sangeetha; Zeng, Qing et al. (2017) Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics. Clin Cancer Res 23:1263-1273
Zheng, Grace X Y; Terry, Jessica M; Belgrader, Phillip et al. (2017) Massively parallel digital transcriptional profiling of single cells. Nat Commun 8:14049
Kroeger Jr, Paul T; Drapkin, Ronny (2017) Pathogenesis and heterogeneity of ovarian cancer. Curr Opin Obstet Gynecol 29:26-34
Yu-Rice, Yi; Edassery, Seby L; Urban, Nicole et al. (2017) Selenium-Binding Protein 1 (SBP1) autoantibodies in ovarian disorders and ovarian cancer. Reproduction 153:277-284
Liao, John B; Swensen, Ron E; Ovenell, Kelsie J et al. (2017) Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancer. Gynecol Oncol 144:480-485
Vragniau, Charles; Hübner, Jens-Martin; Beidler, Peter et al. (2017) Studies on the Interaction of Tumor-Derived HD5 Alpha Defensins with Adenoviruses and Implications for Oncolytic Adenovirus Therapy. J Virol 91:
Kondrashova, Olga; Nguyen, Minh; Shield-Artin, Kristy et al. (2017) Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. Cancer Discov 7:984-998
Au-Yeung, George; Lang, Franziska; Azar, Walid J et al. (2017) Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition. Clin Cancer Res 23:1862-1874

Showing the most recent 10 out of 187 publications